FY2024 EPS Estimates for Ascendis Pharma A/S (NASDAQ:ASND) Decreased by Cantor Fitzgerald
Ascendis Pharma A/S (NASDAQ:ASND – Free Report) – Investment analysts at Cantor Fitzgerald cut their FY2024 earnings per share (EPS) estimates for Ascendis Pharma A/S in a research note issued on Tuesday, October 1st. Cantor Fitzgerald analyst L. Watsek now expects that the biotechnology company will earn ($6.80) per share for the year, down from […]
More Stories
When Your Payment Provider Can No Longer Keep Up
A payment account can work perfectly well until the business starts growing. Sales rise and customers arrive from new countries,...
The Hawk Season 2 Updates: Where Did Season 1 End
Netflix’s 2026 series, The Hawk, has been released. It has received a mixed response from the audience in different parts...
Netflix’s Upcoming Sports Documentary: Mourinho Is Releasing Soon
Football fans, be ready! Netflix is about to drop one of its most-awaited sports documentaries of 2026. Mourinho is a...
Order of the Sinking Star is Ready to Launch on PlayStation 5 and TV
The creator of Braid and The Witness, Jonathan Blow, is returning with an all-new puzzle video game, Order of the...
Netflix’s Upcoming Drama, All the Truth in My Lies: Release Date, Cast, and More
Excited to know about the upcoming Spanish drama on Netflix, All the Truth in My Lies. If you love watching...
Obsession (2026): Release Date, Cast Members, Trailer, Plot, and More
Be Alert: Spoilers Ahead! Are you also a lover of horror shows and looking for upcoming horror movies and series...